Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 20/100

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

Key Takeaway: ClaimsFiler warns uniQure N.V. investors about a securities class action lawsuit, urging those with losses exceeding $100,000 to act before the April 13, 2026, lead plaintiff deadline. This lawsuit follows disclosures that the FDA does not find the data from uniQure's Phase I/II studies adequate for supporting the Biologics License Application for their drug AMT-130. Consequently, uniQure's stock plummeted over 49% on November 3, 2025, indicating serious investor concerns regarding the company's communication and the likelihood of future drug approvals.

Market Sentiment Analysis

CONCERNS & RISKS

  • Shareholders are experiencing significant financial losses due to the drop in stock price.
  • The company's future regarding the FDA approval of AMT-130 is uncertain.
  • Legal action is being taken against uniQure for not disclosing material information.
  • The stock price fell over 49% in response to bad news regarding AMT-130.

Full Press Release Details

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”
On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.
The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

The deadline for filing lead plaintiff applications is April 13, 2026.

What is the class period for uniQure's lawsuit?

The class period for the lawsuit spans from September 24, 2025, to October 31, 2025.

What caused the drop in uniQure's stock price?

uniQure's stock price dropped over 49% after the FDA questioned the adequacy of data for AMT-130.

Who can file a claim in the uniQure lawsuit?

Investors who purchased uniQure shares during the class period can file a claim.

Where can investors get more information about ClaimsFiler?

Investors can visit www.claimsfiler.com for more information.

Last updated: Mar 5, 2026